v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Cash flows from Operating activities    
Net loss $ (41,114) $ (83,619)
Adjustments to reconcile net loss to cash used in operating activities:    
Income from discontinued operations (249) 0
Foreign exchange transaction loss from intercompany 1,031 0
Depreciation and amortization 4,259 679
Gain on deconsolidation (19,336) 0
Gain on sale of property and equipment (58) 0
Non cash interest income on note receivable 0 (364)
Non cash interest expense on debt 3,688 0
Stock-based compensation 8,954 6,319
Shares issued for non-cash consultant expense 0 674
Change in fair value of share liability 0 129
Change in fair value of convertible notes payable 4,028 64,715
Change in fair value of equity investments (1,126) 0
Change in right-of-use lease asset 542 268
Non-cash lease income (199) (22)
Change in deferred taxes (193) 0
Changes in operating assets and liabilities, net of acquisition amounts:    
Accounts receivable (1,383) 89
Receivable from noncontrolling interest 0 28
Inventories (264) (946)
Prepaid expenses and other current assets 2,248 1,318
Other noncurrent assets (1,200) 103
Accounts payable 286 1,107
Accrued expenses 557 (507)
Operating lease liabilities (604) (275)
Other current liabilities (311) (767)
Other noncurrent liabilities 471 0
Net cash used in operating activities - continuing operations (39,973) (11,071)
Cash used for operating activities - discontinued operations (1,121) 0
Net cash used in operating activities (41,094) (11,071)
Cash flows from investing activities    
Purchases of property and equipment (10,227) (4,108)
Purchases of short-term investments (35,425) 0
Proceeds from maturity of short-term investments 47,870 0
Principal collections from lease receivable 279 0
Proceeds from sale of property and equipment 122 0
Purchase of equity investments (14,067) 0
Cash received for acquisition of business, net of cash paid 4,919 0
Cash disposed of upon deconsolidation of subsidiary (50,699) 0
Cash advance in exchanges for note receivable 0 (30,000)
Net cash used in investing activities - continuing operations (57,228) (34,108)
Net cash used in investing activities (57,228) (34,108)
Cash flows from financing activities    
Proceeds from issuance of common stock 0 50,000
Payment of common stock issuance costs 0 (3,239)
Proceeds from exercise of warrants 0 4,915
Proceeds from exercise of options 139 0
Distribution to noncontrolling interest in VIE (472) (79)
Distribution to noncontrolling interest of Renergen (1,109) 0
Proceeds from issuance of debt 53 47
Payment of principal portion of debt (3,719) (802)
Payment of principal portion of finance leases (106) (61)
Net cash (used in) provided by financing activities - continuing operations (5,214) 50,781
Cash provided by financing activities - discontinued operations 45,886 0
Net cash provided by financing activities 40,672 50,781
Net change in cash, cash equivalents and restricted cash (57,650) 5,602
Effect of exchange rate changes on cash, cash equivalents and restricted cash (2,461) 187
Cash, cash equivalents and restricted cash - beginning of period 285,563 61,890
Cash, cash equivalents and restricted cash - end of period 225,452 67,679
Components of cash, cash equivalents, and restricted cash    
Cash and cash equivalents 219,596 67,679
Restricted cash 5,856 0
Total cash, cash equivalents, and restricted cash 225,452 67,679
Supplemental cash flow information:    
Cash paid for Interest 1,829 0
Supplemental disclosures of non-cash investing and financing activities:    
Derecognition of asset as a result of sales-type lease 1,689 0
Lease receivable 1,689 393
Unpaid financing fees 663 0
Purchase of property and equipment included in accounts payable 282 412
Purchase of property and equipment with bank loans 53 0
Right-of-use asset obtained in exchange for operating lease liability 4,600 102
Right-of-use asset obtained in exchange for finance lease liability 53 0
Common stock issued in acquisition of Renergen 92,897 0
Contingent consideration for acquisition of Numed $ 358 $ 0